Insulin Affordability Remains Elusive Despite Policy Changes

Despite legislative actions aimed at curbing the cost of insulin, millions of Americans still struggle to afford the life-saving medication, leading to continued rationing and significant health risks. A decade ago, the high cost of insulin, exacerbated by the death of Alec Smith who was rationing his supply, and repeated price hikes, sparked national outrage and calls for reform.

In response, states began passing laws to cap out-of-pocket insulin costs, with 27 states and Washington, D.C., now having such policies. In 2022, the Inflation Reduction Act included a provision capping insulin prescriptions for Medicare recipients at $35 per month. Drug manufacturers also announced reductions in the cash price for uninsured individuals. However, these measures have not fully resolved the crisis.

Recent surveys reveal persistent problems. A Yale Diabetes Center study found that in 2024, one in four patients treated there reported rationing insulin due to cost, the same rate as in 2017. When including those who rationed due to insurance delays or supply issues, over a third of patients faced difficulties obtaining their medication. A national T1 International survey in 2024 reported that 34% of American insulin users rationed their medicine.

Experts attribute the ongoing affordability issues to several factors. Millions of Americans remain uninsured and face high cash prices, with enrollment in discount programs proving complex and sometimes obstructed by restrictions or stock shortages of lower-priced generics. Furthermore, existing caps have significant loopholes. The federal $35 cap applies only to Medicare, excluding private insurance. State laws often exempt larger, self-funded employer plans, leaving many commercially insured individuals without protection.

Even for those benefiting from caps, navigating the system can be challenging, and actual out-of-pocket costs can exceed the intended cap due to factors like needing multiple types of insulin or pharmacy substitutions. These complexities lead to frustration and continued financial strain.

The consequences of rationing are severe, ranging from diabetic ketoacidosis, a life-threatening condition where blood turns acidic, to long-term health problems like vision and nerve damage due to prolonged high blood sugar.

Advocates are pushing for more comprehensive solutions beyond price caps, emphasizing the need for drug pricing reform, insurance mandates, and exploring public manufacturing of insulin. Some states are beginning to explore government-supported production, while California has launched a program aiming for state-owned facilities to produce insulin at low costs, though this is a long-term endeavor. Public manufacturing, advocates argue, could also address supply chain issues and counter monopolistic practices by pharmaceutical companies.

While immediate resources exist to help individuals struggling with insulin costs, advocates stress that systemic change is necessary. They warn against complacency and encourage public engagement to pressure lawmakers into enacting more comprehensive policies to ensure true insulin affordability.